Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration.

Fiche publication

Date publication

décembre 2024

Journal

Cancer chemotherapy and pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François , Dr ROYER Bernard , Dr VINCENT Julie , Dr BENGRINE-LEFEVRE Leila , Pr SCHMITT Antonin

Tous les auteurs :
Matheux A, Collas L, Grisard M, Goulaieff L, Ghiringhelli F, Bengrine-Lefevre L, Vincent J, Goirand F, Royer B, Schmitt A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39702680

Résumé

The use of plasma uracil measurements to detect dihydropyrimidine dehydrogenase (DPD) deficiency is one of the methods for preventing toxicities associated with fluoropyrimidines, including 5-Fluorouracil (5-FU). Unfortunately, this measurement is subject to variations, that may lead to unnecessary dosage reductions and therefore to a reduced efficacy of treatment. Recently, new factors such as hepatic and renal impairment have been proposed as also influencing uracil concentration. The aim of our study was therefore to study the influence of renal or hepatic function on 5-FU clearance.